A Phase 3 interventional study of Insulin degludec/liraglutide and Insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 38 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-04-09.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 49th largest by enrollment, is one of 6 that started in 2016, is one of 49 in phase 3, and was the 51st registered.
10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 210 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
644 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 26 open now, 30 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 644 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 214th largest by enrollment of the 429 interventional ones that give a count, is one of 20 that started in 2016, is one of 187 in phase 3, and was the 425th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 644 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia. The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide and insulin degludec both in combination with metformin in Japanese subjects with type 2 diabetes mellitus inadequately controlled with basal or pre-mix/combination insulin therapy and oral anti-diabetic drugs.
10,392 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
This study's enrollment of 210 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Insulin degludec/liraglutide
Drug: Insulin degludec
Drug pages: Insulin degludec · Liraglutide
Injected s.c. / subcutaneously (under the skin) once daily
Injected s.c. / subcutaneously (under the skin) once daily
Change in Glycosylated Haemoglobin (HbA1c)
Change from baseline (week 0) in HbA1c after 26 weeks of treatment.
Time frame: week 0, week 26
Change in Body Weight
Change from baseline (week 0) in body weight after 26 weeks of treatment.
Time frame: week 0, week 26
Change in Fasting Plasma Glucose (FPG)
Change from baseline (week 0) in FPG after 26 weeks of treatment.
Time frame: week 0, week 26
Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with or without symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
Time frame: During 26 weeks of treatment
Daily Insulin Dose
Actual daily total insulin dose after 26 weeks.
Time frame: After 26 weeks
Responder (Yes/no): HbA1c Less Than 7.0%
Number of subjects with HbA1c less than 7.0% after 26 weeks.
Time frame: After 26 weeks
Responder (Yes/no): HbA1c Less Than 7.0% and Without Weight Gain
Number of subjects with HbA1c less than 7.0% and without weight gain after 26 weeks.
Time frame: After 26 weeks
Responder (Yes/no): HbA1c Less Than 7.0% Without Treatment Emergent Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
Number of subjects with HbA1c less than 7.0% after 26 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Time frame: After 26 weeks
Responder (Yes/no): HbA1c Less Than 7.0% and Without Weight Gain and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
Number of subjects with HbA1c less than 7.0% and no weight gain after 26 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Time frame: After 26 weeks
Responder (Yes/no): HbA1c Less Than or Equal to 6.5%
Number of subjects with HbA1c less than or equal to 6.5% after 26 weeks.
Time frame: After 26 weeks
Responder (Yes/no): HbA1c Less Than or Equal to 6.5% and Without Weight Gain
Number of subjects with HbA1c less than or equal to 6.5% and without weight gain
Time frame: After 26 weeks
Responder (Yes/no): HbA1c Less Than or Equal to 6.5% Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
Number of subjects with HbA1c less than or equal to 6.5% after 26 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Time frame: After 26 weeks
Responder (Yes/no): HbA1c Less Than or Equal to 6.5% and Without Weight Gain and Without Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes During the Last 12 Weeks of Treatment
Number of subjects with HbA1c less than or equal to 6.5% and no weight gain after 26 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
Time frame: After 26 weeks
Change in Waist Circumference
Change from baseline (week 0) in waist circumference after 26 weeks of treatment.
Time frame: week 0, week 26
Change in Blood Pressure (Systolic and Diastolic)
Change from baseline in blood pressure (systolic and diastolic) after 26 weeks of treatment.
Time frame: week 0, week 26
Self-measured Blood Glucose (SMBG) 9-point Profile (Individual Points in the Profile)
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day.
Time frame: After 26 weeks
Change in SMBG 9-point Profile: Mean of the 9-point Profile
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. Mean of the 9-point profile was defined as the area under the profile (calculated using the trapezoidal method) divided by the measurement time.
Time frame: Week 0, week 26
Change in SMBG 9-point Profile: Mean of Postprandial Plasma Glucose Increments (From Before Meal to 90 Minutes After Breakfast, Lunch and Dinner)
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. The mean increment over all meals was derived as the mean of all available meal increments.
Time frame: Week 0, week 26
Fasting Lipid Profile
Lipid profile includes total cholesterol, low density lipoprotein cholesterol (LDL cholesterol), high density lipoprotein cholesterol (HDL cholesterol), very low density lipoprotein cholesterol (VLDL cholesterol), triglycerides and free fatty acids. Lipid profile parameters are represented as ratio to baseline values.
Time frame: Week 0, week 26
Number of Treatment Emergent Adverse Events (TEAE)
Treatment emergent adverse event is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.
Time frame: During 26 weeks of treatment
Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
Time frame: During 26 weeks of treatment
Number of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA) Definition
Results represent total number of treatment emergent hypoglycaemic episodes that fall under ADA's definition of hypoglycaemia. ADA's definition of hypoglycaemia includes following categories: 1. Severe hypoglycaemia 2. Documented symptomatic hypoglycaemia 3. Asymptomatic hypoglycaemia 4. Probable symptomatic hypoglycaemia 5. Pseudo-hypoglycaemia. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product.
Time frame: During 26 weeks of treatment
Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Nocturnal period: The period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
Time frame: During 26 weeks of treatment
Change in Clinical Evaluation: Fundoscopy or Fundus Photography
The result of the fundus photography/dilated fundoscopy was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' fundoscopy/fundus photography results at screening (week -2 to week 0) and week 26.
Time frame: Screening (week -2 to week 0), week 26
Change in Clinical Evaluation: Electrocardiogram (ECG)
The result of the ECG was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' ECG results at screening (week -2 to week 0) and week 26.
Time frame: Screening (week -2 to week 0), week 26
Change in Pulse
Change in pulse after 26 weeks of treatment.
Time frame: Week 0, week 26
Change From Baseline in Patient Reported Outcomes (PROs) of Treatment: Diabetes Therapy-Related Quality of Life (DTR-QOL)Questionnaire
For the DTR-QOL questionnaire, change from baseline in the 'Total score' and the following four 'Domain scores' were analysed: 1. Burden on social activities and daily activities 2. Anxiety and dissatisfaction with treatment 3. Hypoglycaemia 4. Satisfaction with treatment. The scoring range of 'Total score' was converted to 0-100 (best case response = 100; worst case response = 0). The scoring range for each of four domains was converted to 0-100 (best case response = 100; worst case response = 0).
Time frame: week 0, week 26
Change From Baseline in Patient Reported Outcomes (PROs) of Treatment: EuroQol-5D (EQ-5D-5L) Questionnaire
Overall health state was rated by patients using the EQ-5D-5L visual analogue scale (VAS) and the EQ-5D-5L index score. The EQ-5D-5L VAS is a vertical scale where patients can rank their health from 0 (worst health imaginable) to 100 (best health imaginable). The EQ-5D-5L index score was calculated based on the 5 dimensions, i.e., mobility, self-care, usual activities (e.g., work, study), pain/discomfort and anxiety/depression with five response levels for each dimension, i.e., no problems, slight problems, moderate problems, severe problems and extreme problems. The scores from 5 dimensions are then converted to the EQ-5D-5L index score scale: 0 - 1 (full health/best-case response = 1; death/worst-case response = 0).
Time frame: week 0, week 26
The trial was conducted at 38 sites in Japan as follows: 38 sites screened and 37 sites randomised subjects.
| Milestone | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Started | 105 | 105 |
| Completed | 105 | 98 |
| Not completed | 0 | 7 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Unclassified | 0 | 3 |
Change from baseline (week 0) in HbA1c after 26 weeks of treatment.
| Percentage of HbA1c | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Glycosylated Haemoglobin (HbA1c) | -1.95 ± 1.01 | -0.65 ± 0.98 |
Change from baseline (week 0) in body weight after 26 weeks of treatment.
| Kg | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Body Weight | -0.7 ± 3.5 | 0.7 ± 2.7 |
Change from baseline (week 0) in FPG after 26 weeks of treatment.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Fasting Plasma Glucose (FPG) | -2.81 ± 3.17 | -2.29 ± 2.68 |
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with or without symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
| Number of episodes | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Number of Treatment Emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes | 124 | 109 |
Actual daily total insulin dose after 26 weeks.
| Units | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Daily Insulin Dose | 37.6 ± 11.4 | 41.2 ± 11.5 |
Number of subjects with HbA1c less than 7.0% after 26 weeks.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Yes | 75 | 23 |
| No | 30 | 82 |
Number of subjects with HbA1c less than 7.0% and without weight gain after 26 weeks.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Yes | 50 | 9 |
| No | 55 | 96 |
Number of subjects with HbA1c less than 7.0% after 26 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Yes | 70 | 20 |
| No | 35 | 81 |
Number of subjects with HbA1c less than 7.0% and no weight gain after 26 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Yes | 49 | 7 |
| No | 56 | 94 |
Number of subjects with HbA1c less than or equal to 6.5% after 26 weeks.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Yes | 57 | 9 |
| No | 48 | 96 |
Number of subjects with HbA1c less than or equal to 6.5% and without weight gain
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Yes | 38 | 4 |
| No | 67 | 101 |
Number of subjects with HbA1c less than or equal to 6.5% after 26 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Yes | 53 | 8 |
| No | 52 | 93 |
Number of subjects with HbA1c less than or equal to 6.5% and no weight gain after 26 weeks, who did not experience treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the last 12 weeks of treatment. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Yes | 37 | 3 |
| No | 68 | 98 |
Change from baseline (week 0) in waist circumference after 26 weeks of treatment.
| cm | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Waist Circumference | -0.6 ± 3.8 | 0.1 ± 3.8 |
Change from baseline in blood pressure (systolic and diastolic) after 26 weeks of treatment.
| mmHg | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Systolic blood pressure | -0.6 ± 14.7 | 0.9 ± 13.6 |
| Diastolic blood pressure | 0.9 ± 9.0 | 1.2 ± 9.0 |
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Before breakfast | 6.59 ± 2.32 | 6.53 ± 2.19 |
| 90 minutes after start of breakfast | 11.00 ± 3.67 | 12.02 ± 3.57 |
| Before lunch | 7.22 ± 2.96 | 8.49 ± 3.75 |
| 90 minutes after start of lunch | 10.59 ± 3.17 | 12.84 ± 3.65 |
| Before dinner | 7.39 ± 2.56 | 8.60 ± 3.97 |
| 90 minutes after start of dinner | 11.09 ± 3.24 | 13.27 ± 4.05 |
| At Bedtime | 9.57 ± 3.54 | 11.98 ± 4.17 |
| At 4:00 a.m. | 6.75 ± 1.98 | 7.72 ± 2.90 |
| Before breakfast the following day | 6.14 ± 1.68 | 6.40 ± 2.06 |
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. Mean of the 9-point profile was defined as the area under the profile (calculated using the trapezoidal method) divided by the measurement time.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in SMBG 9-point Profile: Mean of the 9-point Profile | -2.90 ± 2.87 | -1.11 ± 2.68 |
Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, at bedtime, at 4:00 a.m. and before breakfast the following day. The mean increment over all meals was derived as the mean of all available meal increments.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in SMBG 9-point Profile: Mean of Postprandial Plasma Glucose Increments (From Before Meal to 90 Minutes After Breakfast, Lunch and Dinner) | -0.76 ± 3.00 | 0.70 ± 2.93 |
Lipid profile includes total cholesterol, low density lipoprotein cholesterol (LDL cholesterol), high density lipoprotein cholesterol (HDL cholesterol), very low density lipoprotein cholesterol (VLDL cholesterol), triglycerides and free fatty acids. Lipid profile parameters are represented as ratio to baseline values.
| Ratio | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Total cholesterol | 0.90 ± 15.9 | 0.96 ± 13.0 |
| HDL cholesterol | 0.90 ± 17.5 | 0.95 ± 12.2 |
| LDL cholesterol | 0.86 ± 26.7 | 0.95 ± 21.5 |
| VLDL cholesterol | 1.02 ± 50.5 | 0.97 ± 38.2 |
| Triglycerides | 1.02 ± 58.5 | 0.97 ± 39.3 |
| Free fatty acids | 0.86 ± 67.7 | 0.77 ± 55.3 |
Treatment emergent adverse event is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.
| Number of events | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Number of Treatment Emergent Adverse Events (TEAE) | 280 | 210 |
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
| Number of episodes | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Number of Treatment Emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes | 52 | 43 |
Results represent total number of treatment emergent hypoglycaemic episodes that fall under ADA's definition of hypoglycaemia. ADA's definition of hypoglycaemia includes following categories: 1. Severe hypoglycaemia 2. Documented symptomatic hypoglycaemia 3. Asymptomatic hypoglycaemia 4. Probable symptomatic hypoglycaemia 5. Pseudo-hypoglycaemia. Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product.
| Number of episodes | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Number of Treatment Emergent Hypoglycaemic Episodes According to American Diabetes Association (ADA) Definition | 780 | 717 |
Treatment emergent hypoglycaemic episode is defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last day on trial product. Nocturnal period: The period between 00:01 and 05:59 a.m. (both inclusive). Severe or BG confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification or BG confirmed by a plasma glucose value \< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Severe hypoglycaemia according to the ADA definition: an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose concentrations may not be available during an event, but neurological recovery following the return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.
| Number of episodes | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Number of Treatment Emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes | 4 | 8 |
The result of the fundus photography/dilated fundoscopy was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' fundoscopy/fundus photography results at screening (week -2 to week 0) and week 26.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Left eye - at screening visit - normal | 53 | 70 |
| Left eye - at screening visit - Abn, NCS | 6 | 5 |
| Left eye - at screening visit - Abn, CS | 46 | 30 |
| Left eye - week 26 - normal | 54 | 64 |
| Left eye - week 26 - Abn, NCS | 7 | 7 |
| Left eye - week 26 - Abn, CS | 44 | 34 |
| Right eye - at screening visit - normal | 55 | 72 |
| Right eye - at screening visit - Abn, NCS | 7 | 6 |
| Right eye - at screening visit - Abn, CS | 43 | 27 |
| Right eye - week 26 - normal | 52 | 69 |
| Right eye - week 26 - Abn, NCS | 8 | 6 |
| Right eye - week 26 - Abn, CS | 45 | 30 |
The result of the ECG was interpreted by the investigator into following categories: Normal; Abnormal (Abn), Not Clinically significant (NCS); Abnormal, Clinically significant (CS). Reported results are number of subjects with 'normal'; 'Abn, NCS' and 'Abn, CS' ECG results at screening (week -2 to week 0) and week 26.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| At screening visit - normal | 80 | 82 |
| At screening visit - Abn, NCS | 20 | 18 |
| At screening visit - Abn, CS | 5 | 5 |
| Week 26 -normal | 82 | 82 |
| Week 26 - Abn, NCS | 17 | 20 |
| Week 26 - Abn, CS | 6 | 3 |
Change in pulse after 26 weeks of treatment.
| beats per minute | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Pulse | 6.1 ± 11.0 | -0.2 ± 7.1 |
For the DTR-QOL questionnaire, change from baseline in the 'Total score' and the following four 'Domain scores' were analysed: 1. Burden on social activities and daily activities 2. Anxiety and dissatisfaction with treatment 3. Hypoglycaemia 4. Satisfaction with treatment. The scoring range of 'Total score' was converted to 0-100 (best case response = 100; worst case response = 0). The scoring range for each of four domains was converted to 0-100 (best case response = 100; worst case response = 0).
| Score on a scale | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Total score | 7.9 ± 14.8 | 0.1 ± 13.4 |
| Burden on social activities and daily activities | 5.7 ± 17.3 | 0.6 ± 17.1 |
| Anxiety and dissatisfaction with treatment | 12.9 ± 20.8 | 0.4 ± 17.2 |
| Hypoglycaemia | -2.6 ± 25.5 | -1.6 ± 25.9 |
| Satisfaction with treatment | 15.8 ± 22.5 | -0.4 ± 24.7 |
Overall health state was rated by patients using the EQ-5D-5L visual analogue scale (VAS) and the EQ-5D-5L index score. The EQ-5D-5L VAS is a vertical scale where patients can rank their health from 0 (worst health imaginable) to 100 (best health imaginable). The EQ-5D-5L index score was calculated based on the 5 dimensions, i.e., mobility, self-care, usual activities (e.g., work, study), pain/discomfort and anxiety/depression with five response levels for each dimension, i.e., no problems, slight problems, moderate problems, severe problems and extreme problems. The scores from 5 dimensions are then converted to the EQ-5D-5L index score scale: 0 - 1 (full health/best-case response = 1; death/worst-case response = 0).
| Score on a scale | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in VAS score | 6.3 ± 17.8 | -1.0 ± 15.5 |
| Index score | 0.02 ± 0.08 | -0.01 ± 0.11 |
Collected over Week 0 (randomisation) to week 26 (end of treatment) and 7 days after end of treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Degludec/Liraglutide | 0/105 (0%) | 3/105 (2.9%) | 54/105 (51.4%) |
| Insulin Degludec | 0/105 (0%) | 4/105 (3.8%) | 48/105 (45.7%) |
| Event | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 1/105 | 0/105 |
| Cardiac failure congestiveCardiac disorders | 1/105 | 0/105 |
| Cholecystitis acuteHepatobiliary disorders | 0/105 | 1/105 |
| GastroenteritisInfections and infestations | 1/105 | 0/105 |
| Hip fractureInjury, poisoning and procedural complications | 1/105 | 0/105 |
| Loss of consciousnessNervous system disorders | 0/105 | 1/105 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/105 | 1/105 |
| Renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/105 | 1/105 |
| Retinal detachmentEye disorders | 0/105 | 1/105 |
| Event | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 21/105 | 24/105 |
| Diabetic retinopathyEye disorders | 17/105 | 17/105 |
| DiarrhoeaGastrointestinal disorders | 15/105 | 5/105 |
| NauseaGastrointestinal disorders | 10/105 | 4/105 |
| ConstipationGastrointestinal disorders | 9/105 | 4/105 |
| VomitingGastrointestinal disorders | 9/105 | 2/105 |
| Abdominal discomfortGastrointestinal disorders | 8/105 | 5/105 |
| Decreased appetiteMetabolism and nutrition disorders | 8/105 | 0/105 |
Full Analysis Set (FAS) included all randomised subjects (210 subjects).
| Age, Continuous(Years) | Insulin Degludec/Liraglutide | Insulin Degludec | Total |
|---|---|---|---|
| Mean | 56.6 ± 10.4 | 55.5 ± 10.0 | 56.0 ± 10.2 |
| Sex: Female, Male(Participants) | Insulin Degludec/Liraglutide | Insulin Degludec | Total |
|---|---|---|---|
| Female | 35 | 42 | 77 |
| Male | 70 | 63 | 133 |
| Ethnicity (NIH/OMB)(Participants) | Insulin Degludec/Liraglutide | Insulin Degludec | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Unknown or Not Reported | 105 | 105 | 210 |
| Race (NIH/OMB)(Participants) | Insulin Degludec/Liraglutide | Insulin Degludec | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 105 | 105 | 210 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Glycosylated Haemoglobin (HbA1c)(Percentage of HbA1c) | Insulin Degludec/Liraglutide | Insulin Degludec | Total |
|---|---|---|---|
| Mean | 8.61 ± 0.88 | 8.56 ± 0.80 | 8.58 ± 0.84 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Nov 2017, 13 months.
Results were first posted in Mar 2019, 1 year 3 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 13 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Liraglutide